Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 21,483 matching trials from the live ClinicalTrials.gov search.

Filters: Boston, Massachusetts Clear all

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-210, Mitomycin C, Gemcitabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 27
States / cities: Sun City, Arizona • Los Angeles, California • Lakewood, Colorado + 23 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol, Fluticasone Propionate/Salmeterol Combination Product; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more

Conditions: Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Palbociclib, Letrozole, Fulvestrant, Questionnaire Administration, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 70 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 447
States / cities: Anchorage, Alaska • Kingman, Arizona • Arroyo Grande, California + 303 more

Conditions: Acute Myocardial Infarction (AMI)
Interventions: Beta-blocker adherence after an AMI; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Heart Failure
Interventions: Cardiac Resynchronization Therapy, HeartPOD™ System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 9
States / cities: Los Angeles, California • Boston, Massachusetts • Rochester, New York + 5 more

Conditions: Deep Full-thickness Burn Injury (Disorder)
Interventions: realSKIN (skin xenotransplant), Human Cadaver Allograft; Biological
Lead sponsor: XenoTherapeutics, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Augusta, Georgia • Boston, Massachusetts

Conditions: Osteoporosis
Interventions: Bazedoxifene Acetate, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 7,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 205
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 141 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ceritinib, Pemetrexed, Docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 13
States / cities: Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more

Conditions: Healthy
Interventions: Investigational Product - MIB 626, Placebo, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity; Drug · Other
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BIIB078, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Memory Disorders, Alzheimer Disease, Mild Cognitive Impairment
Interventions: Technology based social interactions, No research related technology based social interactions; Behavioral · Other
Lead sponsor: Boston University; Other
Eligibility: Not listed
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: Exercise; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Muscular Atrophy, Spinal
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: Chronic Hepatitis C Virus Infection
Interventions: CTS-1027, Placebo; Drug · Other
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 15 more

Conditions: Long qt Syndrome, Torsade de Pointes
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts • West Roxbury, Massachusetts

Conditions: Renal Cell Carcinoma, Kidney Cancer
Interventions: bevacizumab, temsirolimus; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Atrial Fibrillation
Interventions: Non-Interventional; Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 22 Years and older
Enrollment: 973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: Mission Viejo, California • Palm Springs, California • Atlantis, Florida + 23 more

Conditions: Huntington's Disease
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 28 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Interventions: Pembrolizumab, Patient Observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment; Biological · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 828
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Dalantercept; Biological
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Pancreatic Adenocarcinoma
Interventions: Temsirolimus, Gemcitabine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: sargramostim, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 12
States / cities: Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Drug Resistant Epilepsy
Interventions: photobiomodulation; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

HMO Research Network CERT: Acute Myocardial Infarction

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Cardiac Resynchronization Therapy (CRT) Based Heart Failure Monitoring Study

Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults

Exercise Training in Heart Failure: Changes in Cardiac Structure and Function

A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

Study of CTS-1027 in Hepatitis C Patients

A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

DEFINE AFib (Atrial Fibrillation)

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Infrared Photobiomodulation in Humans With Epilepsy